{"id":"placebo-for-risankizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Adverse events in placebo groups typically reflect natural disease progression or non-specific effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (risankizumab in this case) by comparison. Any observed effects in placebo recipients are attributed to the placebo effect, natural disease progression, or regression to the mean rather than direct pharmacological action.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:58.338Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05969223","phase":"PHASE4","title":"Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-08-10","conditions":"Genital Psoriasis, Scalp Psoriasis","enrollment":214},{"nctId":"NCT03398135","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-28","conditions":"Ulcerative Colitis (UC)","enrollment":1242},{"nctId":"NCT06274554","phase":"PHASE3","title":"Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2024-10-04","conditions":"Crohn's Disease, Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT06063967","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-11-15","conditions":"Crohn's Disease","enrollment":289},{"nctId":"NCT03671148","phase":"PHASE3","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-03-07","conditions":"Psoriatic Arthritis (PsA)","enrollment":444},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03105102","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-09","conditions":"Crohn's Disease","enrollment":1336},{"nctId":"NCT03675308","phase":"PHASE3","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-03-25","conditions":"Psoriatic Arthritis","enrollment":964},{"nctId":"NCT03398148","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-03-07","conditions":"Ulcerative Colitis (UC)","enrollment":1558},{"nctId":"NCT04713592","phase":"PHASE3","title":"Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-02-26","conditions":"Psoriasis","enrollment":174},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":214},{"nctId":"NCT03926169","phase":"PHASE2","title":"A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-03","conditions":"Hidradenitis Suppurativa","enrollment":243},{"nctId":"NCT03105128","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-10","conditions":"Crohn's Disease","enrollment":931},{"nctId":"NCT03104413","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-18","conditions":"Crohn's Disease","enrollment":618},{"nctId":"NCT03706040","phase":"PHASE2","title":"A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-12-27","conditions":"Dermatitis","enrollment":172},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT03875482","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-05-13","conditions":"Psoriasis","enrollment":157},{"nctId":"NCT03518047","phase":"PHASE3","title":"Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-19","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02672852","phase":"PHASE3","title":"BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-29","conditions":"Psoriasis","enrollment":507},{"nctId":"NCT02047110","phase":"PHASE2","title":"BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-28","conditions":"Ankylosing Spondylitis (AS)","enrollment":159},{"nctId":"NCT02719171","phase":"PHASE2","title":"BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04","conditions":"Arthritis, Psoriatic","enrollment":185},{"nctId":"NCT03000075","phase":"PHASE2","title":"BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-02","conditions":"Psoriasis","enrollment":182},{"nctId":"NCT02443298","phase":"PHASE2","title":"Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-06-23","conditions":"Asthma","enrollment":214},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":140,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo for risankizumab","genericName":"placebo for risankizumab","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}